Cara Therapeutics (CARA) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseZacks Investment Research • 10/31/22
Cara Therapeutics to Announce Third Quarter 2022 Financial Results on November 7, 2022GlobeNewsWire • 10/24/22
Wall Street Analysts See a 133% Upside in Cara (CARA): Can the Stock Really Move This High?Zacks Investment Research • 10/18/22
SWK Holdings' Subsidiary, Enteris BioPharma, Receives $5 Million Milestone Payment from Cara TherapeuticsPRNewsWire • 10/10/22
Cara Therapeutics Announces Difelikefalin (KORSUVA®) Injection New Drug Application Has Been Submitted in JapanGlobeNewsWire • 09/28/22
Cara Therapeutics Presents Late-Breaking Results of the KOMFORT Phase 2 Trial of Oral Difelikefalin for Pruritus in Notalgia Paresthetica at the 31st EADV CongressGlobeNewsWire • 09/08/22
Cara Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment ConferenceGlobeNewsWire • 09/06/22
Cara Therapeutics to Host Virtual Notalgia Paresthetica Event on September 20, 2022GlobeNewsWire • 08/24/22
Cara Therapeutics Announces KOMFORT Data Accepted for Late-Breaking Presentation at the 31st EADV CongressGlobeNewsWire • 08/22/22
Kapruvia® approved in Switzerland with additional regulatory decisions expected in H2 2022Business Wire • 08/19/22
Cara Therapeutics, Inc. (CARA) CEO Christopher Posner on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/09/22
Cara Therapeutics to Present at the Canaccord Genuity 42nd Annual Growth ConferenceGlobeNewsWire • 08/03/22
Cara Therapeutics to Announce Second Quarter 2022 Financial Results on August 8, 2022GlobeNewsWire • 08/01/22
Cara Therapeutics Announces Positive Topline Results from KOMFORT Phase 2 Trial of Oral Difelikefalin for the Treatment of Pruritus in Patients with Notalgia ParestheticaGlobeNewsWire • 06/30/22